Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris Sells 15,394 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 15,394 shares of the company’s stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $25.85, for a total value of $397,934.90. Following the completion of the transaction, the chief executive officer now directly owns 1,418,647 shares in the company, valued at $36,672,024.95. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Todd Harris also recently made the following trade(s):

• On Tuesday, October 15th, Todd Harris sold 10,035 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.31, for a total value of $243,950.85.
• On Monday, September 30th, Todd Harris sold 500 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.00, for a total value of $12,000.00.
• On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.01, for a total transaction of $14,406.00.
• On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96.
• On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total transaction of $138,518.38.

Tyra Biosciences Stock Performance

NASDAQ TYRA opened at $25.98 on Friday. The business’s fifty day moving average is $22.18 and its 200 day moving average is $19.42. The company has a market capitalization of $1.37 billion, a PE ratio of -15.37 and a beta of 1.01. Tyra Biosciences, Inc. has a fifty-two week low of $10.38 and a fifty-two week high of $27.17.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. On average, sell-side analysts forecast that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Wall Street Analysts Forecast Growth

TYRA has been the topic of a number of research reports. Wedbush restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Thursday, August 8th. HC Wainwright raised their target price on Tyra Biosciences from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Oppenheimer upped their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Finally, Piper Sandler started coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.80.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds have recently modified their holdings of the company. RA Capital Management L.P. boosted its stake in shares of Tyra Biosciences by 43.9% in the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after acquiring an additional 3,180,155 shares during the period. BVF Inc. IL boosted its holdings in shares of Tyra Biosciences by 70.1% during the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after purchasing an additional 1,921,599 shares during the last quarter. Perceptive Advisors LLC grew its position in shares of Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after purchasing an additional 338,208 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Tyra Biosciences by 18.6% in the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after purchasing an additional 140,833 shares during the last quarter. Finally, Kynam Capital Management LP increased its stake in Tyra Biosciences by 51.4% in the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after acquiring an additional 175,000 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.